Form 8-K - Current report:
SEC Accession No. 0000950170-25-110654
Filing Date
2025-08-21
Accepted
2025-08-21 16:05:28
Documents
10
Period of Report
2025-08-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K atos-20250821.htm   iXBRL 8-K 46346
  Complete submission text file 0000950170-25-110654.txt   157460

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20250821.xsd EX-101.SCH 28514
12 EXTRACTED XBRL INSTANCE DOCUMENT atos-20250821_htm.xml XML 4681
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 251240759
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)